Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome

Fig. 1

Prevalence of BAF/PBAF genes mutations in 43,728 patients with different cancer types (a) and overall survival of patients treated with immune-checkpoint inhibitors (ICI) according to BAF/PBAF mutational status and tumor mutational burden (b-d). a Prevalence of ARID1A, ARID1B, ARID2, PBRM1, SMARCA4, or SMARCB1 genes mutations in 43,728 patients with different cancer types (b) Kaplan-Meir curves of overall survival in 1661 patients treated with (ICI) according to BAF/PBAF gene status for the overall cohort (b) and in patients with low (< 10 mutations/megabase) (c), and high (> 10 mutations/megabase) (d) tumor mutational burden. Red curves: BAF/PBAF mutated tumors, blue curves: BAF/PBAF wild-type tumors

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us